Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-UMIN000003986
JPRN-UMIN000003986
Completed
Phase 2

Phase II study of S-1 for non-small lung cancer after failure of two or three prior chemotherapy regimens - Phase II study of 3rd-line S-1 for NSCLC

ational Hospital Organization Asahikawa Medical Cencer0 sites40 target enrollmentAugust 4, 2010
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionson Small Cell Lung Cancer (NSCLC)

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
on Small Cell Lung Cancer (NSCLC)
Sponsor
ational Hospital Organization Asahikawa Medical Cencer
Enrollment
40
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 4, 2010
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
ational Hospital Organization Asahikawa Medical Cencer

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • •1\. Previous histories of drug allergy, which may increase the risk of this study. 2\. Serious concomitant infection or high\-grade fever exceeding 38 deg C or more. 3\. Usages of oral steroids or immunosuppressive drugs. 4\. Serious complications including severe cardiovascular disease, cerebrovascular disease, severe hypertension, active peptic ulcer, uncontrolled diabetes. 5\. Interstitial pneumonia or pulmonary fibrosis on chest X\-ray or CT scans. 6\. Any prior treatments with S\-1 or UFT. 7\. Any coelomic fluids (pleural, pericardial, or ascites), which require emergent treatment. 8\. Symptomatic brain metastases. 9\. Other active multiple cancers. 10\. Severe heart diseases. 11\. Psychiatric conditions, which may increase the risks associated with the study participation. 12\. Pregnant or nursing women. 13\. Other conditions, on which the judgment of the investigator would make the patient inappropriate for entry.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Unknown
Not Applicable
S-1 as second line for non-small cell lung cancer with preexisting interstitial pneumonia: phase II study.non-small cell lung cancer
JPRN-UMIN000022165Hamamatsu University School of Medicine28
Recruiting
Phase 2
An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung CancerCarcinoma, Non-Small-Cell Lung Cancer (NSCLC)
NCT06693336ToLymph Inc.42
Active, not recruiting
Not Applicable
A PHASE II TRIAL ON NON-SMALL-CELL LUNG CANCER STEM CELLS SENSITIVITY ASSAY (LUCAS)Histologically/cytologically confirmed diagnosis of metastatic NSCLC.Possibility to obtain tumor tissue form primary tumor or from an accessible metastatic site, or possibility to collect any neoplastic effusion.Performance status of 0-1 according to ECOG score.Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2012-001440-22-IT
Terminated
Phase 1
Debio 1143 in Combination With Carboplatin and Paclitaxel in Patient With Advanced Solid MalignanciesSolid Tumors
NCT01930292Debiopharm International SA31
Not yet recruiting
Not Applicable
Designing information for lung cancer patients in decision making.Patients presenting with a stage I non-small cell lung cancer (NSCLC).Patienten met stadium I niet kleincellige longkanker.
NL-OMON2116225